ODTX vs JBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ODTX · Odyssey Therapeutics$19.23 ▲ 1.85%
JBIO · Jade Biosciences$15.07 ▲ 6.88%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ODTX +17.1%
- JBIO -41.6%
Head to head
| Metric | ODTX | JBIO |
|---|---|---|
| Price | $19.23 | $15.07 |
| Change today | ▲ 1.85% | ▲ 6.88% |
| Market cap | $924.35M | $958.41M |
| Return, 3 months | -13.3% | -30.6% |
| Return, year to date | – | -2.3% |
| Return, 1 year | – | +64.0% |
| P/E (TTM) | – | – |
| P/B | 2.5 | 2.2 |
| P/E percentile vs own 5y | 49th | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | – |
| Net profit growth (YoY) | -28.0% | -73.5% |
| Gross margin | – | – |
| Operating margin | -161,887.9% | – |
| Net margin | -161,643.4% | – |
| Return on equity | -38.0% | -47.8% |
| Analyst target vs. price | +83.7% | +235.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 52 |
| 30-day volatility | 78.6% | 49.8% |
| Max drawdown, 1 year | -42.3% | -50.1% |
| Trend read | Leaning bullish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JBIO is the largest of the group by market value.
- JBIO has been the calmest stock over the last 30 days.